Department of Medical Oncology, University College London Hospital, London, UK.
Department of Medical Oncology, St Bartholomew's Hospital, London, UK.
Future Oncol. 2019 Jun;15(16):1845-1853. doi: 10.2217/fon-2019-0057. Epub 2019 Apr 30.
Maintenance therapy with PARP inhibitors has heralded a new era in the management of recurrent epithelial ovarian cancer. The greatest effect is seen in women with tumors but those without this mutation also benefit. However, in most patients, the drugs eventually fail to prevent progression, so alternative strategies are needed. The SOLO1 trial randomized women with -mutated advanced ovarian cancer to olaparib or placebo maintenance after first-line chemotherapy. Olaparib significantly improved progression-free survival to a degree that has not been seen in other first-line trials in ovarian cancer. This landmark trial is likely to change practice for this group of women. Here, we focus on the SOLO1 results in the context of the current management of advanced ovarian cancer.
PARP 抑制剂的维持治疗开创了复发性上皮性卵巢癌治疗的新纪元。这种治疗方法对存在 BRCA 突变的肿瘤患者效果最为显著，但无 BRCA 突变的患者也能从中获益。然而，在大多数患者中，这些药物最终无法阻止疾病进展，因此需要其他策略。SOLO1 试验将携带 BRCA 突变的晚期卵巢癌患者随机分为奥拉帕利维持治疗组和安慰剂组，用于一线化疗后维持治疗。奥拉帕利显著改善了无进展生存期，其改善程度在卵巢癌的其他一线试验中尚未见到。这项具有里程碑意义的试验可能会改变这部分女性的治疗实践。在此，我们结合晚期卵巢癌的当前治疗方法，重点讨论 SOLO1 试验的结果。
